Previous 10 | Next 10 |
Menlo Therapeutics (NASDAQ: MNLO ) initiated with Overweight rating and $8 (161% upside) price target at Barclays. More news on: Menlo Therapeutics Inc., Molecular Templates, Inc., Passage Bio, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
The following slide deck was published by Molecular Templates, Inc. in conjunction with this Read more ...
Molecular Templates (NASDAQ: MTEM ): Q4 GAAP EPS of -$0.41 misses by $0.19 . Revenue of $6.2M (+32.5% Y/Y) beats by $1.59M . Press Release More news on: Molecular Templates, Inc., Earnings news and commentary, Healthcare stocks news,
AUSTIN, Texas, March 12, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted bio...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
AUSTIN, Texas, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bo...
Molecular Templates ( MTEM +7.6% ) is up on below-average volume in response to its announcement that dosing is underway in a Phase 1 clinical trial conducted by collaboration partner Takeda Pharmaceutical Company ( TAK -0.7% ) evaluating TAK-169 in patients with relapsed/refractory ...
AUSTIN, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bo...
AUSTIN, Texas, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), provided a corpo...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 138 weeks of public selections as part of this ongoing live forward-testing. In...
News, Short Squeeze, Breakout and More Instantly...
Molecular Templates Inc. Company Name:
MTEM Stock Symbol:
NASDAQ Market:
Molecular Templates Inc. Website:
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineere...